{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:57:21Z","timestamp":1778504241481,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Youth Fund of Second Hospital of Tianjin Medical University","award":["2018ydey03"],"award-info":[{"award-number":["2018ydey03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11255-019-02265-4","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T14:31:21Z","timestamp":1566916281000},"page":"2189-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-9359","authenticated-orcid":false,"given":"Ya-nan","family":"Man","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"issue":"1","key":"2265_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2265_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/02841860510029743","volume":"44","author":"JE Damber","year":"2005","unstructured":"Damber JE (2005) Endocrine therapy for prostate cancer. Acta Oncol 44(6):605\u2013609","journal-title":"Acta Oncol"},{"issue":"1","key":"2265_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2015.06.021","volume":"367","author":"A Katzenwadel","year":"2015","unstructured":"Katzenwadel A, Wolf P (2015) Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett 367(1):12\u201317","journal-title":"Cancer Lett"},{"issue":"1","key":"2265_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2217\/fon.14.145","volume":"11","author":"M Tucci","year":"2015","unstructured":"Tucci M, Scagliotti GV, Vignani F (2015) Metastatic castration-resistant prostate cancer: time for innovation. Future Oncol (Lond, Engl) 11(1):91\u2013106","journal-title":"Future Oncol (Lond, Engl)"},{"issue":"5","key":"2265_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"2","key":"2265_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160","journal-title":"Lancet Oncol"},{"issue":"9747","key":"2265_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (Lond Engl) 376(9747):1147\u20131154","journal-title":"Lancet (Lond Engl)"},{"issue":"3","key":"2265_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"5","key":"2265_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422","journal-title":"N Engl J Med"},{"issue":"7203","key":"2265_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436\u2013444","journal-title":"Nature"},{"issue":"4","key":"2265_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263\u2013274","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2265_CR12","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2265_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","volume":"10","author":"NA Cannon","year":"2015","unstructured":"Cannon NA, Meyer J, Iyengar P et al (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280\u2013285","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2265_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1245\/s10434-014-4097-4","volume":"22","author":"L Rossi","year":"2015","unstructured":"Rossi L, Santoni M, Crabb SJ et al (2015) High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol 22(4):1377\u20131384","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2265_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/0284186X.2016.1260772","volume":"56","author":"C Buttigliero","year":"2017","unstructured":"Buttigliero C, Pisano C, Tucci M et al (2017) Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncol 56(4):555\u2013562","journal-title":"Acta Oncol"},{"key":"2265_CR16","doi-asserted-by":"publisher","first-page":"7538647","DOI":"10.1155\/2017\/7538647","volume":"2017","author":"K Uemura","year":"2017","unstructured":"Uemura K, Kawahara T, Yamashita D et al (2017) Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy. Biomed Res Int 2017:7538647","journal-title":"Biomed Res Int"},{"issue":"3","key":"2265_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/annonc\/mdt581","volume":"25","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Templeton AJ, Omlin A et al (2014) Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 25(3):657\u2013662","journal-title":"Ann Oncol"},{"issue":"7","key":"2265_CR18","doi-asserted-by":"publisher","first-page":"e0158952","DOI":"10.1371\/journal.pone.0158952","volume":"11","author":"V Conteduca","year":"2016","unstructured":"Conteduca V, Crabb SJ, Jones RJ et al (2016) Persistent neutrophil to lymphocyte ratio\u2009>\u20093 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS One 11(7):e0158952","journal-title":"PLoS One"},{"issue":"23","key":"2265_CR19","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y et al (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20(23):6212\u20136222","journal-title":"Clin Cancer Res"},{"issue":"34","key":"2265_CR20","doi-asserted-by":"publisher","first-page":"54564","DOI":"10.18632\/oncotarget.10515","volume":"7","author":"C Lolli","year":"2016","unstructured":"Lolli C, Basso U, Derosa L et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 7(34):54564\u201354571","journal-title":"Oncotarget"},{"issue":"22","key":"2265_CR21","doi-asserted-by":"publisher","first-page":"33210","DOI":"10.18632\/oncotarget.8901","volume":"7","author":"A Passardi","year":"2016","unstructured":"Passardi A, Scarpi E, Cavanna L et al (2016) Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7(22):33210\u201333219","journal-title":"Oncotarget"},{"issue":"1","key":"2265_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40880-017-0243-2","volume":"36","author":"K Wang","year":"2017","unstructured":"Wang K, Diao F, Ye Z et al (2017) Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer 36(1):75","journal-title":"Chin J Cancer"},{"key":"2265_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fphar.2016.00376","volume":"7","author":"C Lolli","year":"2016","unstructured":"Lolli C, Caffo O, Scarpi E et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol 7:376","journal-title":"Front Pharmacol"},{"issue":"6","key":"2265_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eururo.2011.01.034","volume":"59","author":"TM Morgan","year":"2011","unstructured":"Morgan TM, Tang D, Stratton KL et al (2011) Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 59(6):923\u2013928","journal-title":"Eur Urol"},{"issue":"8 Suppl","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"1433s","DOI":"10.1093\/jn\/124.suppl_8.1433S","volume":"124","author":"RK Chandra","year":"1994","unstructured":"Chandra RK, Kumari S (1994) Nutrition and immunity: an overview. J Nutr 124(8 Suppl):1433s\u20131435s","journal-title":"J Nutr"},{"issue":"Suppl 1","key":"2265_CR26","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1038\/sj.ejcn.1601819","volume":"57","author":"A Marcos","year":"2003","unstructured":"Marcos A, Nova E, Montero A (2003) Changes in the immune system are conditioned by nutrition. Eur J Clin Nutr 57(Suppl 1):S66\u2013S69","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"2265_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1081\/IMM-120022979","volume":"32","author":"Y Gao","year":"2003","unstructured":"Gao Y, Zhou S, Jiang W et al (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32(3):201\u2013215","journal-title":"Immunol Invest"},{"issue":"5","key":"2265_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1067\/msy.2001.112963","volume":"129","author":"DE Rivadeneira","year":"2001","unstructured":"Rivadeneira DE, Grobmyer SR, Naama HA et al (2001) Malnutrition-induced macrophage apoptosis. Surgery 129(5):617\u2013625","journal-title":"Surgery"},{"issue":"2","key":"2265_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0008-8749(92)90088-7","volume":"139","author":"JV Reynolds","year":"1992","unstructured":"Reynolds JV, Redmond HP, Ueno N et al (1992) Impairment of macrophage activation and granuloma formation by protein deprivation in mice. Cell Immunol 139(2):493\u2013504","journal-title":"Cell Immunol"},{"issue":"3","key":"2265_CR30","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/j.clgc.2017.01.008","volume":"15","author":"W Cai","year":"2017","unstructured":"Cai W, Kong W, Dong B et al (2017) Pretreatment serum prealbumin as an independent prognostic indicator in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors as first-line target therapy. Clin Genitourin Cancer 15(3):e437\u2013e446","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"2265_CR31","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s00268-012-1766-y","volume":"36","author":"H Kawai","year":"2012","unstructured":"Kawai H, Ota H (2012) Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 36(12):2853\u20132857","journal-title":"World J Surg"},{"issue":"5","key":"2265_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/bjc.2012.15","volume":"106","author":"P Kelly","year":"2012","unstructured":"Kelly P, Paulin F, Lamont D et al (2012) Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer 106(5):955\u2013961","journal-title":"Br J Cancer"},{"issue":"17","key":"2265_CR33","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.7150\/jca.21134","volume":"8","author":"L Fan","year":"2017","unstructured":"Fan L, Chi C, Guo S et al (2017) Serum pre-albumin predicts the clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone. J Cancer 8(17):3448\u20133455","journal-title":"J Cancer"},{"issue":"5","key":"2265_CR34","first-page":"745","volume":"88","author":"JH Beer","year":"2002","unstructured":"Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88(5):745\u2013749","journal-title":"Thromb Haemost"},{"issue":"2","key":"2265_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/107602960100700211","volume":"7","author":"SC Koh","year":"2001","unstructured":"Koh SC, Tham KF, Razvi K et al (2001) Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could d-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 7(2):141\u2013148","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2265_CR36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.juro.2013.10.073","volume":"191","author":"M Pichler","year":"2014","unstructured":"Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191(4):920\u2013925","journal-title":"J Urol"},{"issue":"6","key":"2265_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/sj.bjc.6605547","volume":"102","author":"V Seebacher","year":"2010","unstructured":"Seebacher V, Polterauer S, Grimm C et al (2010) The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 102(6):952\u2013956","journal-title":"Br J Cancer"},{"issue":"25","key":"2265_CR38","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","volume":"27","author":"C Ay","year":"2009","unstructured":"Ay C, Vormittag R, Dunkler D et al (2009) D-dimer and prothrombin fragment 1\u2009+\u20092 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27(25):4124\u20134129","journal-title":"J Clin Oncol"},{"issue":"2","key":"2265_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/pcan.2016.6","volume":"19","author":"Y Wang","year":"2016","unstructured":"Wang Y, Yin W, Wang Z et al (2016) Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer Prostatic Dis 19(2):209\u2013215","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2265_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1471-2407-6-147","volume":"6","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Kitayama J, Kanno N et al (2006) Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147","journal-title":"BMC Cancer"},{"key":"2265_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.suronc.2013.12.001","volume":"23","author":"A Paramanathan","year":"2014","unstructured":"Paramanathan A, Saxena A, Morris DL (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 23:31\u201339","journal-title":"Surg Oncol"},{"key":"2265_CR42","doi-asserted-by":"publisher","first-page":"e83279","DOI":"10.1371\/journal.pone.0083279","volume":"9","author":"DJ Pinato","year":"2014","unstructured":"Pinato DJ, Stavraka C, Flynn MJ et al (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One 9:e83279","journal-title":"PLoS One"},{"key":"2265_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123\u2013134","journal-title":"Nat Rev Cancer"},{"key":"2265_CR44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576\u2013590","journal-title":"Cancer Cell"},{"key":"2265_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","volume":"4","author":"W Liang","year":"2016","unstructured":"Liang W, Ferrara N (2016) The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res 4:83\u201391","journal-title":"Cancer Immunol Res"},{"key":"2265_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Cassatella MA, Costantini C et al (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519\u2013531","journal-title":"Nat Rev Immunol"},{"key":"2265_CR47","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Allavena P, Sica A et al (2011) Cancer-related inflammation. Nature 454:436\u2013444","journal-title":"Nature"},{"issue":"2","key":"2265_CR48","first-page":"516","volume":"27","author":"K Valenzuela-Landaeta","year":"2012","unstructured":"Valenzuela-Landaeta K, Rojas P, Basfi-fer K et al (2012) Nutritional assessment for cancer patient. Nutr Hosp 27(2):516\u2013523","journal-title":"Nutr Hosp"},{"key":"2265_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12894-016-0133-y","volume":"16","author":"S Yamashita","year":"2016","unstructured":"Yamashita S, Kohjimoto Y, Iguchi T et al (2016) Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol 16:13","journal-title":"BMC Urol"},{"key":"2265_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1471-2407-6-147","volume":"6","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Kitayama J, Kanno N et al (2006) Hyper fibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147","journal-title":"BMC Cancer"},{"key":"2265_CR51","first-page":"979Y985","volume":"14","author":"S Olterauer","year":"2009","unstructured":"Olterauer S, Grimm C, Seebacher V et al (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979Y985","journal-title":"Oncologist"},{"key":"2265_CR52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/1471-2407-14-566","volume":"14","author":"YJ Shu","year":"2014","unstructured":"Shu YJ, Weng H, Bao RF et al (2014) Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer 14:566","journal-title":"BMC Cancer"},{"key":"2265_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1349-7006.2009.01115.x","volume":"100","author":"S Zheng","year":"2009","unstructured":"Zheng S, Shen J, Jiao Y et al (2009) Platelets and fibrinogen facilitate each other in protecting tumour cells from natural killer cytotoxicity. Cancer Sci 100:859\u2013865","journal-title":"Cancer Sci"},{"key":"2265_CR54","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-09-3465","volume":"70","author":"KA Steinbrecher","year":"2010","unstructured":"Steinbrecher KA, Horowitz NA, Blevins EA et al (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fbrinogen. Cancer Res 70:2634\u20132643","journal-title":"Cancer Res"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-019-02265-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T06:28:23Z","timestamp":1650176903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-019-02265-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02265-4","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}